BioMaxima S.A. (WSE:BMX)
Poland · Delayed Price · Currency is PLN 11.60
-0.14 (-1.19%)
Apr 16, 2026, 5:00 PM CET
BioMaxima Market Cap
BioMaxima has a market cap or net worth of 49.23 million as of April 16, 2026. Its market cap has decreased by -6.83% in one year.
Market Cap
49.23M
Enterprise Value
64.08M
Revenue
59.11M
Ranking
n/a
PE Ratio
78.27
Stock Price
11.60
Market Cap Chart
Since July 21, 2010, BioMaxima's market cap has increased from 11.40M to 49.23M, an increase of 331.68%. That is a compound annual growth rate of 9.73%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 16, 2026 | 48.64M | -3.73% |
| Dec 30, 2025 | 50.53M | 12.62% |
| Dec 30, 2024 | 44.87M | -34.84% |
| Dec 29, 2023 | 68.85M | -35.28% |
| Dec 30, 2022 | 106.38M | -6.37% |
| Dec 30, 2021 | 113.62M | -4.71% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 27, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Diagnostyka | 6.01B |
| NEUCA | 3.20B |
| Synektik Spólka Akcyjna | 2.57B |
| Celon Pharma | 1.14B |
| Genomtec | 67.79M |
| Urteste | 64.84M |
| Read-Gene | 62.49M |
| Sygnis | 42.10M |